May 3, 2022
Holland & Knight Health Dose: May 3, 2022
![Holland & Knight Health Dose](/-/media/images/twittercards/blogs/healthdose.png?rev=28e9e198d69c446c9fd8409f368b8252&sc_lang=en&hash=7A2FDB35CB2B5C08E70E64C1347FE915)
Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector.
This week's topics include:
- COVID-19 Relief Funding
- User Fee Agreements & Other Health Priorities in the House
- Healthy Future Task Force Releases Set of Treatment Recommendations
- CMS Releases Final 2023 Medicate Advantage (MA)/Part D Rule
- CMS Finalizes 2023 Benefit and Payment Parameters for Marketplace Plans
- FDA Sets June Dates to Review COVID-19 Vaccines
- FDA Revamps Office of Product Evaluation and Quality as Path Forward for Reimbursing FDA-Approved Breakthrough Devices Remains Unclear
- MIPS 2022 Extreme and Uncontrollable Circumstances Portal Now Open